NervGen announces first participant dosed in Phase 3 study of NVG-291
NGEN•NervGen said the first participant has been dosed in RESTORE, a Phase 3 study of NVG-291 for chronic spinal cord injury; enrollment completion is expected in the second half of 2027, with topline data in the first half of 2028.
1. RESTORE trial begins
NervGen Pharma Corp said the first participant has been dosed in RESTORE, a Phase 3 registrational study evaluating NVG-291 in chronic spinal cord injury. Enrollment completion is expected in the second half of 2027, and topline data are expected in the first half of 2028.
